ABT-126 monotherapy in mild-to-moderate Alzheimer’s dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension

BACKGROUND: Results from a phase 2a study indicated that treatment with the novel α7 nicotinic acetylcholine receptor agonist ABT-126 25 mg once daily (QD) was associated with a trend for improvement in cognition in subjects with mild-to-moderate Alzheimer’s dementia (AD). A phase 2b program was des...

Descripción completa

Detalles Bibliográficos
Autores principales: Gault, Laura M., Lenz, Robert A., Ritchie, Craig W., Meier, Andreas, Othman, Ahmed A., Tang, Qi, Berry, Scott, Pritchett, Yili, Robieson, Weining Z.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5067903/
https://www.ncbi.nlm.nih.gov/pubmed/27756421
http://dx.doi.org/10.1186/s13195-016-0210-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5067903/
https://www.ncbi.nlm.nih.gov/pubmed/27756421
http://dx.doi.org/10.1186/s13195-016-0210-1

Ejemplares similares